Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
Belinda Nghiema, Xiaotun Zhanga, Hung-Ming Lama,b, Lawrence D. Truec, Ilsa Colemand, Celestia S. Higanoa,e, Peter S. Nelsond,e, Colin C. Pritcharde,f, Colm Morrisseya
a Department of Urology, University of Washington, Seattle, WA, USA; b State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau(SAR), China; c Department of Pathology, University of Washington, Seattle, WA, USA; d Divison of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; e Department of Medicine, University of Washington, Seattle, WA, USA; f Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
Belinda Nghiema, Xiaotun Zhanga, Hung-Ming Lama,b, Lawrence D. Truec, Ilsa Colemand, Celestia S. Higanoa,e, Peter S. Nelsond,e, Colin C. Pritcharde,f, Colm Morrisseya
a Department of Urology, University of Washington, Seattle, WA, USA; b State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau(SAR), China; c Department of Pathology, University of Washington, Seattle, WA, USA; d Divison of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; e Department of Medicine, University of Washington, Seattle, WA, USA; f Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
摘要 Objective: Although the utility of immunohistochemistry (IHC) for assessing mismatch repair (MMR) protein expression has been demonstrated in solid tumors including primary prostate cancer (PCa), its utility has not been assessed in castration-resistant PCa (CRPC). Methods: Tissue microarrays were constructed from 127 radical prostatectomies and 155 CRPC metastases from 50 patients. MMR (MLH1, MSH2, MSH6, and PMS2) expression was assessed by IHC and gene expression arrays. Associations between MMR protein expression in PCa and CRPC and biochemical recurrence (BCR) or time from diagnosis to death respectively were determined. Results: There was no correlation between levels of MMR protein and BCR. Absence of MSH2 and MSH6 was the most pronounced at 15% and 22% in PCa and 17.8% and 16% in CRPC patients, respectively. MSH2 and MSH6 protein were absent in 9.4% and 8% of PCa and CRPC respectively. Absence of individual MMR proteins did not correlate with BCR or time from diagnosis to death. However absent MSH2/MSH6 in CRPC was associated with shorter time to death (p=0.0006). Loss of MSH2 was verified at the gene expression level. This finding correlated with microsatellite instability previously reported in this CRPC cohort.
Abstract: Objective: Although the utility of immunohistochemistry (IHC) for assessing mismatch repair (MMR) protein expression has been demonstrated in solid tumors including primary prostate cancer (PCa), its utility has not been assessed in castration-resistant PCa (CRPC). Methods: Tissue microarrays were constructed from 127 radical prostatectomies and 155 CRPC metastases from 50 patients. MMR (MLH1, MSH2, MSH6, and PMS2) expression was assessed by IHC and gene expression arrays. Associations between MMR protein expression in PCa and CRPC and biochemical recurrence (BCR) or time from diagnosis to death respectively were determined. Results: There was no correlation between levels of MMR protein and BCR. Absence of MSH2 and MSH6 was the most pronounced at 15% and 22% in PCa and 17.8% and 16% in CRPC patients, respectively. MSH2 and MSH6 protein were absent in 9.4% and 8% of PCa and CRPC respectively. Absence of individual MMR proteins did not correlate with BCR or time from diagnosis to death. However absent MSH2/MSH6 in CRPC was associated with shorter time to death (p=0.0006). Loss of MSH2 was verified at the gene expression level. This finding correlated with microsatellite instability previously reported in this CRPC cohort.
Belinda Nghiem, Xiaotun Zhang, Hung-Ming Lam, Lawrence D. True, Ilsa Coleman, Celestia S. Higano, Peter S. Nelson, Colin C. Pritchard, Colm Morrissey. Mismatch repair enzyme expression in primary and castrate resistant prostate cancer[J]. Asian Journal of Urology, 2016, 3(4): 223-228.
Belinda Nghiem, Xiaotun Zhang, Hung-Ming Lam, Lawrence D. True, Ilsa Coleman, Celestia S. Higano, Peter S. Nelson, Colin C. Pritchard, Colm Morrissey. Mismatch repair enzyme expression in primary and castrate resistant prostate cancer. Asian Journal of Urology, 2016, 3(4): 223-228.
Shia J, Stadler Z, Weiser MR, Rentz M, Gonen M, Tang LH, et al. Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma:how reliable are biopsy samples? Am J Surg Pathol 2011;35:447-54.
[2]
Christians F, Connolly D, Tsuchiya K, True L, Loeb L. Lack of microsatellite instability in human prostate-cancer. Int J Oncol 1995;6:1173-6.
[3]
Suzuki H, Komiya A, Aida S, Akimoto S, Shiraishi T, Yatani R, et al. Microsatellite instability and other molecular abnormalities in human prostate cancer. Jpn J Cancer Res 1995;86:956-61.
[4]
Sharma M, Predeus AV, Kovacs N, Feig M. Differential mismatch recognition specificities of eukaryotic MutS homologs, MutSalpha and MutSbeta. Biophys J 2014;106:2483-92.
[5]
Pal T, Permuth-Wey J, Sellers TA. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer 2008;113:733-42.
[6]
Burger M, Denzinger S, Hammerschmied CG, Tannapfel A, Obermann EC, Wieland WF, et al. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med (Berl) 2006;84:833-41.
[7]
Norris AM, Woodruff RD, D'Agostino Jr RB, Clodfelter JE, Scarpinato KD. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate 2007;67:214-25.
[8]
Norris AM, Gentry M, Peehl DM, D'Agostino Jr R, Scarpinato KD. The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009;18:57-64.
[9]
Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, et al. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 2002;94:690-9.
[10]
Prtilo A, Leach FS, Markwalder R, Kappeler A, Burkhard FC, Cecchini MG, et al. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J Urol 2005;174:1814-8.
[11]
Zeinalian M, Emami MH, Naimi A, Salehi R, HashemzadehChaleshtori M. Immunohistochemical analysis of mismatch repair proteins in Iranian colorectal cancer patients at risk for lynch syndrome. Iran J Cancer Prev 2015;8:11-7.
[12]
Rosty C, Walsh MD, Lindor NM, Thibodeau SN, Mundt E, Gallinger S, et al. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry. Fam Cancer 2014;13:573-82.
[13]
Fredriksson H, Ikonen T, Autio V, Matikainen MP, Helin HJ, Tammela TL, et al. Identification of germline MLH1 alterations in familial prostate cancer. Eur J Cancer 2006;42:2802-6.
[14]
Soravia C, van der Klift H, Brundler MA, Blouin JL, Wijnen J, Hutter P, et al. Prostate cancer is part of the hereditary nonpolyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A 2003;121A:159-62.
[15]
Leach FS, Velasco A, Hsieh JT, Sagalowsky AI, McConnell JD. The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP. J Urol 2000;164:1830-3.
[16]
Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, et al. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001;61:4112-21.
[17]
Yeh CC, Lee C, Dahiya R. DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem Biophys Res Commun 2001;285:409-13.
[18]
Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87.
[19]
Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 2011;108:17087-92.
[20]
Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun 2014;5:4988.
[21]
Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-53.
[22]
Zhang X, Coleman IM, Brown LG, True LD, Kollath L, Lucas JM, et al. SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin Cancer Res 2015;21:4698-708.
[23]
Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011;6. e27970.
[24]
Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 2016;22:369-78.
[25]
Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 2008;10:301-7.
[26]
Hendriks Y, Franken P, Dierssen JW, De LW, Wijnen J, Dreef E, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 2003;162:469-77.
[27]
Coppola D, Nicosia SV, Doty A, Sellers TA, Lee JH, Fulp J, et al. Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer. Anticancer Res 2012;32:4963-9.
[28]
Resnick KE, Frankel WL, Morrison CD, Fowler JM, Copeland LJ, Stephens J, et al. Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. Gynecol Oncol 2010;117:234-8.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
